Form 4: Conduit Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Simon Jeremy Fry acquired 29,354 shares of Conduit Pharmaceuticals Inc. common stock in lieu of a $26,125 cash retainer.

Summary

• On March 30, 2025, Simon Jeremy Fry, a director of Conduit Pharmaceuticals Inc., acquired 29,354 shares of common stock.
• The shares were issued under the 2023 Stock Incentive Plan.
• The acquisition was in lieu of $26,125 in accrued cash retainers under the Issuer's Non-Employee Director Compensation Program.
• The price per share was $0.89.
• Following the transaction, Fry directly owns 31,354 shares of Conduit Pharmaceuticals Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine part of director compensation. The director taking shares in lieu of cash is a slightly positive sign.

Positives

• A director's decision to take shares in lieu of cash may signal confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for directors to receive stock as part of their compensation.

Related Party Transactions

• The issuance of shares to the director in lieu of cash compensation is a related party transaction.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning their interests with those of other shareholders.

Key Dates

Keywords

Conduit Pharmaceuticals, Director, Share Acquisition, Stock Incentive Plan, Simon Jeremy Fry, CDT, Form 4